KMYY(SH:600518)2020-06-17 16:00Financial Performance - Operating revenue dropped by 76.13% to CNY 1.17 billion year-on-year[4] - Net profit attributable to shareholders was a loss of CNY 296.63 million, a decrease of 552.28% compared to the same period last year[4] - Basic earnings per share were -CNY 0.060, a decline of 561.54% year-on-year[4] - The company's operating revenue decreased due to adjustments in the pharmaceutical industry policies, leading to a focus on core business and a decline in business volume[12] - The company reported a net profit loss of CNY 494,540,858 in Q1 2020, compared to a net profit of CNY 126,182,140 in Q1 2019, representing a significant decline[23] - The total comprehensive income for Q1 2020 was a loss of ¥297,270,145.80, compared to a profit of ¥61,012,226.88 in Q1 2019[21] Cash Flow - Net cash flow from operating activities decreased by 69.91% to CNY 202.82 million[4] - The net cash flow from operating activities was 202,816,854.80, a decrease of 69.91% compared to the previous year[12] - Cash flow from operating activities generated a net amount of CNY 202,816,854.80 in Q1 2020, down from CNY 673,948,510.00 in Q1 2019, a decrease of about 70%[24] - Total cash inflow from operating activities in Q1 2020 was 871,909,209.54 RMB, down from 4,689,143,140.31 RMB in the same period last year, representing a decrease of approximately 81.4%[26] - Cash outflow from operating activities in Q1 2020 was 936,106,455.51 RMB, compared to 3,686,412,471.29 RMB in Q1 2019, indicating a reduction of about 74.7%[26] Assets and Liabilities - Total assets decreased by 1.53% to CNY 63.60 billion compared to the end of the previous year[4] - The company's intangible assets decreased from 2,022,461,560.26 to 1,338,644,803.48, reflecting a reduction in asset value[16] - Total liabilities amounted to ¥43,245,665,264.13, a decrease from ¥43,935,237,255.88 in the previous period, reflecting a reduction of approximately 1.57%[17] - The company's total equity decreased to ¥22,611,658,505.49 from ¥23,106,199,363.49, a decline of about 2.14%[19] - The total non-current liabilities increased to ¥25,072,484,123.27 from ¥15,018,015,567.44, marking an increase of approximately 66.8%[19] Shareholder Information - The total number of shareholders at the end of the reporting period was 181,588[6] - The largest shareholder, Kangmei Industrial Investment Holdings Co., Ltd., held 32.75% of the shares[6] - The total number of preferred shareholders at the end of the reporting period was 8[8] - The top ten preferred shareholders held a total of 30% of the shares, with the largest shareholder holding 9,000,000 shares[8] Expenses - The operating cost for Q1 2020 was ¥835,387,976.74, reflecting a 76.64% decrease from ¥3,575,908,591.88 in the previous period[10] - The company experienced a significant decrease in sales expenses, which fell by 71.49% from ¥369,254,611.00 to ¥105,262,715.34[10] - Research and development expenses decreased due to reduced investment in R&D projects compared to the previous year[12] - Research and development expenses decreased to ¥14,436,906.09 in Q1 2020 from ¥21,522,150.98 in Q1 2019, a reduction of 33%[20] Government Support - The company received government subsidies amounting to CNY 36.45 million during the period[5] Other Financial Metrics - The weighted average return on equity decreased by 1.99 percentage points to -1.73%[4] - The company reported a significant increase in non-recurring losses, with a total of CNY 323.38 million attributed to non-recurring gains and losses[4] - The company reported a significant increase in financial expenses, totaling ¥513,206,606.74 in Q1 2020, compared to ¥497,913,387.85 in Q1 2019[20] - The company recorded an investment loss of ¥1,026,122.21 in Q1 2020, contrasting with an investment income of ¥38,835,826.96 in Q1 2019[20]